Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | AGXT | P21549 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17269304 | 0.81 | MAOB (0.58) | IDO1AGXTTSHRALDH1A1MAOB | |
| SCHEMBL675840 | 0.79 | IDO1 (0.46) | IDO1AGXTTSHRALDH1A1MAOB | |
| SCHEMBL7717207 | 0.79 | IDO1 (0.46) | IDO1AGXTTSHRALDH1A1MAOB | |
| SCHEMBL7717208 | 0.79 | IDO1 (0.46) | IDO1AGXTTSHRALDH1A1MAOB | |
| SCHEMBL1257815 | 0.79 | IDO1 (0.46) | IDO1AGXTTSHRALDH1A1MAOB | |
| SCHEMBL7566541 | 0.79 | IDO1 (0.52) | IDO1AGXTTSHRALDH1A1MAOB | |
| SCHEMBL17259184 | 0.78 | TSHR (0.48) | IDO1AGXTTSHRALDH1A1TRPA1 | |
| SCHEMBL15797835 | 0.78 | TSHR (0.48) | IDO1AGXTTSHRALDH1A1TRPA1 | |
| SCHEMBL29447243 | 0.76 | IDO1 (0.43) | IDO1AGXTTSHRALDH1A1MAOB | |
| SCHEMBL6506525 | 0.76 | IDO1 (0.43) | IDO1AGXTTSHRALDH1A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881825-B1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130178468-A1 | HIV INTEGRASE INHIBITORS | VACCA JOSEPH P (US) | 2013-07-11 | — | — | US | disclosed |
| US-8293731-B2 | HIV integrase inhibitors | Merck Sharp + Dohme Corp. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8138200-B2 | Compositions and methods for double-targeting virus infections and targeting cancer cells | WAKE FOREST UNIVERSITY (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110275621-A1 | HIV INTEGRASE INHIBITORS | SCHERING CORPORATION | 2011-11-10 | — | — | US | disclosed |
| US-7968564-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100204201-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100184718-A1 | Compositions and Methods for Double-Targeting Virus Infections and Targeting Cancer Cells | WAKE FOREST UNIVERSITY | 2010-07-22 | — | — | US | disclosed |
| US-7741315-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7638528-B2 | Compositions and methods for targeting cancer cells | WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE (US) | 2009-12-29 | — | — | US | disclosed |
| WO-2006121831-A2 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| US-7026469-B2 | Compositions and methods of double-targeting virus infections and cancer cells | WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1389970-A4 | COMPOSITIONS AND METHODS OF DOUBLE-TARGETING VIRUS INFECTIONS AND CANCER CELLS | UNIV WAKE FOREST (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040161398-A1 | Compositions and methods for targeting cancer cells | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2004-08-19 | — | — | US | disclosed |
| EP-1389970-A2 | COMPOSITIONS AND METHODS OF DOUBLE-TARGETING VIRUS INFECTIONS AND CANCER CELLS | WAKE FOREST UNIVERSITY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6670341-B1 | Phosphocholine moiety covalently conjugated with one or more antiviral agents (e.g. nucleoside analogue, protease inhibitor, etc.) to a lipid backbone | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2003-12-30 | — | — | US | disclosed |
| WO-2002087465-A2 | COMPOSITIONS AND METHODS OF DOUBLE-TARGETING VIRUS INFECTIONS AND CANCER CELLS | WAKE FOREST UNIVERSITY (US) | 2002-11-07 | — | — | WO | disclosed |
| EP-1228080-A2 | COMPOSITIONS AND METHODS FOR DOUBLE-TARGETING VIRUS INFECTIONS AND TARGETING CANCER CELLS | WAKE FOREST UNIVERSITY (US) | 2002-08-07 | — | — | EP | disclosed |
| US-20020082242-A1 | Compositions and methods of double-targeting virus infections and cancer cells | WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE | 2002-06-27 | — | — | US | disclosed |
| WO-2001034614-A2 | COMPOSITIONS AND METHODS FOR DOUBLE-TARGETING VIRUS INFECTIONS AND TARGETING CANCER CELLS | WAKE FOREST UNIVERSITY (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040161398-A1 | Compositions and methods for targeting cancer cells | PHOSPHO1, SGMS1, LPCAT1 | IDO1 867/4885AGXT 3096/4885TSHR 4616/4885 |
| US-20100204201-A1 | HIV INTEGRASE INHIBITORS | REV1, CDKN1A, CCNI | IDO1 183/4885AGXT 1984/4885TSHR 4000/4885 |
| US-20130178468-A1 | HIV INTEGRASE INHIBITORS | REV1, CDKN1A, CCNI | IDO1 183/4885AGXT 1984/4885TSHR 4000/4885 |
| US-20020082242-A1 | Compositions and methods of double-targeting virus infections and cancer cells | PHOSPHO1, PIGS, SMPD1 | IDO1 773/4885AGXT 2781/4885TSHR 4614/4885 |
| US-20100184718-A1 | Compositions and Methods for Double-Targeting Virus Infections and Targeting Cancer Cells | PHOSPHO1, PIGS, SMPD1 | IDO1 1004/4885AGXT 2997/4885TSHR 4613/4885 |
| US-20110275621-A1 | HIV INTEGRASE INHIBITORS | REV1, CDKN1A, CCNI | IDO1 183/4885AGXT 1984/4885TSHR 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.